Stocktoria
Pacira BioSciences, Inc. PCRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-02-03
Pacira BioSciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% |
| Net margin | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% |
| FCF margin | 18.8% | 25.5% | 20.7% | 17.3% | 14.7% |
| Return on assets | 0.6% | -6.4% | 2.7% | 0.9% | 2.0% |
| Return on equity | 1.0% | -12.8% | 4.8% | 2.1% | 5.7% |
| Debt / equity | 0.54× | 0.75× | 0.60× | 0.89× | — |
| Current ratio | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 |
| Revenue growth | 3.6% | 3.9% | 1.2% | 23.1% | 26.0% |
Source: SEC EDGAR filings · CIK 0001396814 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.